BioCentury | Dec 10, 2016
Product Development

AML advances

Treatment paradigms in most cancers have followed a predictable if sometimes slow progression from chemotherapy, to agents that target features prevalent among a classically defined cancer type, to personalized approaches targeting features specific to an...
BioCentury | Mar 2, 2015
Strategy

Sosei finds its R&D engine

...first major acquisitions was arguably also its most successful: the 2005 acquisition of U.K. company Arakis Ltd....
...long-acting muscarinic receptor antagonist (LAMA) that was already partnered with Novartis. Although Sosei also gained Arakis'...
BioCentury | Jan 31, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Terminally differentiated stem cell-derived cells with negligible immunogenicity Terminally differentiated stem cell-derived cells show negligible immunogenicity, suggesting they could be useful for transplant and cell...
BioCentury | Jun 28, 2010
Strategy

Sosei's Consolidation Play

...model is to find new indications for old drugs. In 2005, it acquired U.K. reprofiler Arakis Ltd....
...QVA149 , a fixed-dose combination of NVA237 and the adrenergic receptor beta 2 agonist indacaterol. Arakis...
BioCentury | May 31, 2010
Finance

Performance Counts

...Tables Class of 2003: Exits Returned at least 2X Target Acquirer Acq value Raised Focus Arakis Ltd....
BioCentury | Jul 23, 2009
Cover Story

A stimulating new role for rapamycin

Although marketed as an immunosuppressant, Wyeth 's Rapamune sirolimus (rapamycin) may now also have utility as an immunostimulatory vaccine adjuvant that raises the number of protective memory CD8 T cells, according to findings by Emory...
BioCentury | Jun 25, 2009
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Infectious disease Mammalian target of rapamycin (mTOR; FRAP; RAFT1) Studies in mice and in macaques suggest that rapamycin could help increase the efficacy of...
BioCentury | May 14, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Nicotinamide nucleotide adenylyltransferase 3 (NMNAT3) A study in mice suggests that increasing mitochondrial expression of NMNAT3 could help delay...
BioCentury | May 19, 2008
Company News

Sosei genitourinary, neurology news

...acquisition of Arakis Ltd. (see BioCentury, July 25, 2005). The only compound Sosei is keeping from Arakis...
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...Bay City Capital; General Electric; New Enterprise Associates; ProQuest Investments; Versant Ventures; and company management Arakis...
Items per page:
1 - 10 of 83
BioCentury | Dec 10, 2016
Product Development

AML advances

Treatment paradigms in most cancers have followed a predictable if sometimes slow progression from chemotherapy, to agents that target features prevalent among a classically defined cancer type, to personalized approaches targeting features specific to an...
BioCentury | Mar 2, 2015
Strategy

Sosei finds its R&D engine

...first major acquisitions was arguably also its most successful: the 2005 acquisition of U.K. company Arakis Ltd....
...long-acting muscarinic receptor antagonist (LAMA) that was already partnered with Novartis. Although Sosei also gained Arakis'...
BioCentury | Jan 31, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Terminally differentiated stem cell-derived cells with negligible immunogenicity Terminally differentiated stem cell-derived cells show negligible immunogenicity, suggesting they could be useful for transplant and cell...
BioCentury | Jun 28, 2010
Strategy

Sosei's Consolidation Play

...model is to find new indications for old drugs. In 2005, it acquired U.K. reprofiler Arakis Ltd....
...QVA149 , a fixed-dose combination of NVA237 and the adrenergic receptor beta 2 agonist indacaterol. Arakis...
BioCentury | May 31, 2010
Finance

Performance Counts

...Tables Class of 2003: Exits Returned at least 2X Target Acquirer Acq value Raised Focus Arakis Ltd....
BioCentury | Jul 23, 2009
Cover Story

A stimulating new role for rapamycin

Although marketed as an immunosuppressant, Wyeth 's Rapamune sirolimus (rapamycin) may now also have utility as an immunostimulatory vaccine adjuvant that raises the number of protective memory CD8 T cells, according to findings by Emory...
BioCentury | Jun 25, 2009
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Infectious disease Mammalian target of rapamycin (mTOR; FRAP; RAFT1) Studies in mice and in macaques suggest that rapamycin could help increase the efficacy of...
BioCentury | May 14, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Nicotinamide nucleotide adenylyltransferase 3 (NMNAT3) A study in mice suggests that increasing mitochondrial expression of NMNAT3 could help delay...
BioCentury | May 19, 2008
Company News

Sosei genitourinary, neurology news

...acquisition of Arakis Ltd. (see BioCentury, July 25, 2005). The only compound Sosei is keeping from Arakis...
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...Bay City Capital; General Electric; New Enterprise Associates; ProQuest Investments; Versant Ventures; and company management Arakis...
Items per page:
1 - 10 of 83